Introduction: This quiz collection on Techniques for Diversification & Expansion is tailored for M.Pharm students studying MIP 204T – Entrepreneurship Management. It focuses on strategic options pharmaceutical firms use to grow—product and market diversification, horizontal and vertical integration, licensing, joint ventures, mergers & acquisitions, contract manufacturing/research, and geographic expansion. Questions emphasize regulatory, operational and commercial considerations unique to the pharma sector: technology transfer, GMP scale-up, intellectual property, due diligence, synergies, and risk mitigation. These MCQs aim to reinforce conceptual clarity, support exam preparation, and encourage application of strategic tools (Ansoff, BCG) to real-world pharmaceutical growth scenarios.
Q1. Which diversification strategy involves a pharmaceutical company developing new products that are technologically related to its existing product lines to leverage existing R&D capabilities?
- Conglomerate diversification
- Concentric diversification
- Horizontal diversification
- Market development
Correct Answer: Concentric diversification
Q2. Which expansion technique is best described as acquiring a manufacturing firm that supplies active pharmaceutical ingredients (APIs) to achieve tighter supply chain control?
- Horizontal integration
- Backward vertical integration
- Forward vertical integration
- Conglomerate merger
Correct Answer: Backward vertical integration
Q3. In the Ansoff Matrix, which strategy focuses on selling existing pharmaceutical products into new geographic markets?
- Product development
- Diversification
- Market penetration
- Market development
Correct Answer: Market development
Q4. A pharmaceutical company licenses out rights to a patented drug to another firm in a different territory while retaining manufacturing—this arrangement is best classified as which technique?
- Out-licensing
- Equity joint venture
- Contract manufacturing
- Franchising
Correct Answer: Out-licensing
Q5. Which method of expansion commonly used in pharma minimizes capital investment by outsourcing clinical trial operations to a specialized organization?
- Co-marketing
- Contract research (CRO partnerships)
- Vertical integration
- Spin-off
Correct Answer: Contract research (CRO partnerships)
Q6. Which diversification approach poses the highest regulatory and scientific risk for a pharmaceutical firm due to entering unrelated industries?
- Concentric diversification
- Horizontal diversification
- Conglomerate diversification
- Backward integration
Correct Answer: Conglomerate diversification
Q7. When evaluating an acquisition target in pharma, which due diligence area is most critical to assess potential post-merger regulatory liabilities?
- Market share analysis
- Manufacturing compliance and regulatory records
- Employee satisfaction surveys
- Office lease terms
Correct Answer: Manufacturing compliance and regulatory records
Q8. A brand-extension in pharmaceuticals typically involves:
- Introducing a product in an unrelated consumer category
- Using an established drug brand to launch a closely related formulation or dosage form
- Acquiring a competitor to increase market share
- Divesting non-core business units
Correct Answer: Using an established drug brand to launch a closely related formulation or dosage form
Q9. Which strategic alliance model allows two pharma firms to co-develop a novel molecule while sharing development costs and future revenues?
- Licensing-in
- Co-development joint venture
- Franchise agreement
- Contract manufacturing
Correct Answer: Co-development joint venture
Q10. In portfolio management, which BCG quadrant would a mature, high-market-share blockbuster drug typically occupy?
- Question Marks
- Dogs
- Stars
- Cows (Cash Cows)
Correct Answer: Cows (Cash Cows)
Q11. Which expansion technique is most appropriate for rapidly entering multiple international markets while minimizing local regulatory burden and capital outlay?
- Greenfield wholly-owned subsidiaries
- Franchising to local non-pharma partners
- Strategic licensing and local partnerships
- Hostile takeover of local firms
Correct Answer: Strategic licensing and local partnerships
Q12. A pharmaceutical firm pursuing horizontal integration is primarily aiming to:
- Gain control over suppliers
- Enter upstream production of raw materials
- Acquire competitors or similar product lines to increase market share
- Diversify into unrelated consumer goods
Correct Answer: Acquire competitors or similar product lines to increase market share
Q13. Which risk is especially significant when a pharma company pursues rapid geographic expansion without adequate local regulatory expertise?
- Currency exchange rate risk only
- Reputational and non-compliance risk leading to market withdrawal
- Lower R&D productivity
- Loss of core manufacturing capability
Correct Answer: Reputational and non-compliance risk leading to market withdrawal
Q14. Out-licensing a molecule during early development is often chosen to:
- Increase capital expenditure on manufacturing
- Transfer development risk and obtain upfront and milestone payments
- Retain all future commercial rights globally
- Avoid any regulatory submissions
Correct Answer: Transfer development risk and obtain upfront and milestone payments
Q15. A spin-off in the pharmaceutical industry is most likely used to:
- Merge two unrelated business units
- Create a separate company for a non-core asset or R&D program
- Acquire a competitor’s product line
- Enter a joint venture with a supplier
Correct Answer: Create a separate company for a non-core asset or R&D program
Q16. Which concept describes cost advantages achieved when producing a wider range of related pharmaceutical products using shared facilities and expertise?
- Economies of scale
- Economies of scope
- Diseconomies of scale
- Price discrimination
Correct Answer: Economies of scope
Q17. When a pharma company acquires another to obtain a complementary product pipeline and reduce overlapping R&D, the expected benefit is termed:
- Regulatory arbitrage
- Operational redundancy
- Synergy
- Cannibalization
Correct Answer: Synergy
Q18. Which contractual expansion technique transfers manufacturing responsibilities to a specialist while the originator retains marketing control?
- Out-licensing of IP
- Contract manufacturing organization (CMO) agreement
- Equity merger
- Franchise model
Correct Answer: Contract manufacturing organization (CMO) agreement
Q19. In assessing potential M&A deals in pharma, what is the primary purpose of a technology transfer audit?
- To evaluate marketing strategies
- To ensure transferred processes can be reproduced at receiving sites under GMP
- To measure social media presence
- To negotiate employee contracts
Correct Answer: To ensure transferred processes can be reproduced at receiving sites under GMP
Q20. Which expansion approach can help a pharmaceutical firm quickly broaden its therapeutic portfolio while sharing regulatory and commercial risk with a partner?
- Building in-house capabilities only
- Strategic alliances or co-development agreements
- Divestment of core assets
- Conglomerate diversification into unrelated sectors
Correct Answer: Strategic alliances or co-development agreements
